Celgene announces dismissal of suit against Barr Laboratories following withdrawal of thalidomide ANDA
Client(s) Celgene Corporation
Jones Day successfully represented Celgene Corporation in a Hatch-Waxman patent litigation against Barr Laboratories, Inc., in connection with Celgene's brand thalidomide product, Thalomid®. In May 2010, Barr withdrew its Abbreviated New Drug Application (ANDA) for thalidomide with the US Food and Drug Administration. As a result of Barr's withdrawal, the US District Court for the District of New Jersey has granted the parties' requested dismissal of all claims, including the dismissal with prejudice of Barr's patent and antitrust counterclaims.
Celgene Corp. et al. v. Barr Labs, Inc., Civil Action No. 2-07-00286 (D. N.J.)